First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...
Introduction of AVT05 supported by NHS England tender award in the United KingdomREYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech ...
Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...
The latest update is out from Alvotech ( (ALVO) ).
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a ...
Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis First Subcutaneous Anti-TNF to Launch ...
Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition. “Ulcerative colitis is a complex, lifelong ...
Simponi works by blocking tumor necrosis factor (TNF), which plays an important role in causing abnormal inflammatory and immune responses. Previously approved to treat rheumatoid arthritis, psoriatic ...
Icelandic biosimilars specialist Alvotech (Nasdaq: ALVO) has begun launching Gobivaz (golimumab), the world’s first ...
It is looking likely that patients with rheumatoid arthritis will get access to Merck Sharpe and Dohme's Simponi on the National Health Service, after cost regulators provisionally recommended funding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback